L. L. Froelich

发表

Phosphatidylinositol 3-kinase activation is required for insulin-stimulated sodium transport in A6 cells.

B. Blazer-Yost, C. Vlahos, R. Record, 1998, American journal of physiology. Endocrinology and metabolism.

Phosphatidylinositol 3-kinase activation is required for insulin-stimulated sodium transport in A6 cells.

B. Blazer-Yost, C. Vlahos, R. Record, 1998, American journal of physiology. Endocrinology and metabolism.

The discovery of LY293111, a novel, potent and orally active leukotriene B4 receptor antagonist of the biphenylphenol class.

W. Jackson, M. Sofia, S. Silbaugh, 1997, Advances in experimental medicine and biology.

Pharmacologic actions of the second generation leukotriene B4 receptor antagonist LY293111: in vivo pulmonary studies

A. Bendele, W. Jackson, M. Sofia, 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

Aerosolized LTB4 produces delayed onset increases in pulmonary gas trapping.

A. Bendele, W. Jackson, M. Sofia, 1996, Prostaglandins, leukotrienes, and essential fatty acids.

Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist.

J. S. Sawyer, S. Spaethe, L. L. Froelich, 1995, Biochemical pharmacology.

Quinoline-substituted dihydroindoles as cysLT1 (LTD4 receptor) antagonists

S. Silbaugh, J. S. Sawyer, P. Stengel, 1996 .

Leukotriene B4 receptor antagonists: the LY255283 series of hydroxyacetophenones.

W. Jackson, G. Staten, T. Goodson, 1992, Journal of medicinal chemistry.

Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.

R. J. Boyd, R. Schultz, W. Jackson, 1999, The Journal of pharmacology and experimental therapeutics.

Leukotriene B4 (LTB4) receptor antagonists: a series of (hydroxyphenyl)pyrazoles.

R. W. Harper, R. J. Boyd, W. Jackson, 1994, Journal of medicinal chemistry.

alkoxyphenol leukotriene B4 receptor antagonists

W. Jackson, M. Sofia, S. Silbaugh, 1992 .

-alkoxyphenol leukotriene B4 receptor antagonists: effect of a chroman carboxylic acid.

W. Jackson, M. Sofia, S. Silbaugh, 1992 .

Structural analogues of LY292728, a highly potent xanthone dicarboxylic acid leukotriene B4 receptor antagonist: spatial positioning of the secondary acid group

W. Jackson, J. S. Sawyer, L. L. Froelich, 1994 .

Acid unit modifications of 1,2,4,5-substituted hydroxyacetophenones and the effect on in vitro and in vivo LTB4 receptor antagonism

W. Jackson, M. Sofia, S. Silbaugh, 1993 .

Benzophenone dicarboxylic acid antagonists of leukotriene B4. 2. Structure-activity relationships of the lipophilic side chain.

W. Jackson, L. L. Froelich, D. M. Gapinski, 1990, Journal of medicinal chemistry.

Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity.

J. T. Metz, J. Masters, T. Craft, 2000, Journal of medicinal chemistry.

Anthranilamide inhibitors of factor Xa.

J. A. Kyle, J. Masters, T. Goodson, 2007, Bioorganic & medicinal chemistry letters.

Investigation of factor Xa inhibitors containing non-amidine S1 elements.

R. Towner, J. Masters, T. Craft, 2005, Bioorganic & medicinal chemistry letters.

Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.

J. A. Kyle, N. Chirgadze, S. Briggs, 2000, Journal of Medicinal Chemistry.

Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors.

C. Murray, J. Masters, T. Craft, 2007, Bioorganic & medicinal chemistry letters.

Benzophenone dicarboxylic acid antagonists of leukotriene B4. 1. Structure-activity relationships of the benzophenone nucleus.

W. Jackson, L. L. Froelich, D. M. Gapinski, 1990, Journal of medicinal chemistry.

Design, synthesis, and pharmacological evaluation of potent xanthone dicarboxylic acid leukotriene B4 receptor antagonists.

R. J. Boyd, W. Jackson, J. S. Sawyer, 1993, Journal of medicinal chemistry.

Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonist.

B. H. Petersen, B. Cerimele, S. Spaethe, 1996, British journal of clinical pharmacology.

Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists.

M. Sofia, S. Silbaugh, J. S. Sawyer, 1993, Journal of Medicinal Chemistry.

Leukotriene B4 (LTB4) Receptor Antagonists: A Series of (Hydroxyphenyl) pyrazoles.

R. W. Harper, R. J. Boyd, W. Jackson, 1994 .

Diaryl ether/carboxylic acid derivatives of LY255283: receptor antagonists of leukotriene B4

W. Jackson, J. S. Sawyer, L. L. Froelich, 1993 .

Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982.

R. J. Boyd, W. Jackson, L. L. Froelich, 1992, The Journal of pharmacology and experimental therapeutics.

Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist.

W. Jackson, J. S. Sawyer, P. Floreancig, 1995, Journal of medicinal chemistry.

Synthesis and pharmacologic activity of hydroxyacetophenone-substituted benzophenone/xanthone leukotriene B4 receptor antagonists

W. Jackson, J. S. Sawyer, L. L. Froelich, 1993 .

Synthetic and Structure-Activity Studies on Acid-Substituted 2- Arylphenols: Discovery of 2-(2-Propyl-3-(3-(2-ethyl-4-(4-fluorophenyl)- 5-hydroxyphenoxy)propoxy)phenoxy)benzoic Acid, a High-Affinity Leukotriene B4 Receptor Antagonist.

W. Jackson, M. Sofia, S. Silbaugh, 1996 .

Phosphatidylinositol 3-kinase activation is required for insulin-stimulated sodium transport in A6 cells.

B. Blazer-Yost, C. Vlahos, R. Record, 1998, American Journal of Physiology.

Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.

J. A. Kyle, Michael Robert Wiley, N. Chirgadze, 2000, Journal of Medicinal Chemistry.